Clinical Trials
35 trialsPilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
CivaDerm(TM) Surface Therapy Pilot Study
CivaTech Oncology
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Zr89 + PET Companion Trial
Abramson Cancer Center at Penn Medicine
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
MELRIV-1
Centre Jean Perrin
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
University of Southern California
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Ohio State University Comprehensive Cancer Center
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
Rutgers, The State University of New Jersey
pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma
TuHURA Biosciences, Inc.
Non-invasive Fluorescent Imaging System for Imaging Mohs Tumor
University of Missouri-Columbia
Topical Vitamin C for Treatment of Basal Cell Cancer
Center for Biomedical Research, Inc.
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Northwestern University
NICE
Rhode Island Hospital
Topical Itraconazole in the Treatment of Basal Cell Carcinoma
Johns Hopkins University
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
Mayo Clinic
Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma
Washington University School of Medicine
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
Mayo Clinic
Topical Itraconazole in Treating Patients With Basal Cell Cancer
Stanford University
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
Mayo Clinic
Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions
University of Pittsburgh
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
Stanford University
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma
University of Pittsburgh
IMCgp100 in Advanced Unresectable Melanoma
University of Pennsylvania
AK
Washington University School of Medicine
Mel55
University of Virginia
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Case Comprehensive Cancer Center
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Northwestern University
Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery
Mayo Clinic
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
Massachusetts General Hospital
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity
Memorial Sloan Kettering Cancer Center
K5
Siemens Molecular Imaging